Ryan Specialty (RYAN)
NYSEFinancialsInsurance - BrokersSnapshot 2026-09-04
$41.91-1.02%
Close 2026-09-04 · 1-day change
NYSEFinancialsInsurance - BrokersSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Ryan Specialty grows revenue about 8% a year. The company repurchased $260 million in shares recently, expanding its buyback program to $600 million. Profit margins are stable near 29%. The CFO buying shares shows confidence in the business.
Ryan Specialty cut its guidance for 2026 and faces probes that could hurt results. Margins are expected to fall 100-150 basis points this year. Revenue growth could slow below analyst expectations.
The stock trades about 25% above our fair value near $33, reflecting roughly 8% revenue growth. Our fair value is 17% below the Street median price target, suggesting some optimism is priced in that we do not fully share.
Breaks if: Share repurchase program reduced below $600 million or buybacks halt
Expand the share repurchase authorization by an additional $300 million to a total of $600 million to return capital to shareholders.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady growth. The current thesis is stable, supported by recent strong financial results and ongoing management priorities.
The market appears to have priced in elevated expectations, reflecting a fragile valuation due to weak execution quality. This suggests that any negative news could lead to a significant reaction.
Management is on track with its priorities, including share repurchases and maintaining dividends. However, there is a near-term risk of missing earnings, although the probability is relatively low.
The thesis hinges on the performance of sector bellwethers like MRSH, AON, and AJG. Positive earnings from these companies could provide a favorable backdrop, while any misses could negatively impact RYAN.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. The share repurchase program was initially authorized at $300 million in 2025-Q4 and 2026-Q1, then increased by $300 million to $600 million total authorization by 2026-Q2. The company repurchased $260 million of shares in 2026-Q2, demonstrating active capital return. The trajectory is delivering on the expanded repurchase authorization.
“Expanding our repurchase authorization by an additional $300 million.”
“Board approved a share repurchase program authorizing up to $300 million of Class A common stock.”
“Company Announces $300 million Share Repurchase Authorization.”
Breaks if: Dividend cut below $0.13 per share
Continue paying a regular quarterly dividend of $0.13 per share to shareholders.
Stated as a priority in 4 of last 4 quarters. The company maintained a quarterly dividend of $0.13 per share in 2026-Q1 and 2026-Q2, up from $0.12 in 2025-Q3. Dividend payments have been consistent and the company declared the dividend regularly, indicating delivery on this capital allocation priority.
“Board declared a quarterly dividend of $0.13 per share payable August 25, 2026.”
“Board declared a regular quarterly dividend of $0.13 per share payable May 26, 2026.”
“Board declared and increased the regular quarterly dividend by 8.3% to $0.13 per share.”
“Declared a regular quarterly dividend of $0.12 per share.”
Breaks if: Margin decline exceeds 150 basis points in FY26
Manage Adjusted EBITDAC Margin to decline moderately by 100 to 150 basis points in 2026 compared to prior year.
Stated as a priority in 3 of last 3 quarters. The company updated 2026 guidance to Adjusted EBITDAC Margin down 50-100 basis points from prior guidance of 100-150 basis points decline. Actual margin was 35.7% in 2026-Q2, slightly down from 36.1% in 2025-Q2, showing limited margin contraction. The trajectory is mixed with modest margin decline consistent with guidance.
“Guiding to an Adjusted EBITDAC Margin that is down 50 - 100 basis points for 2026.”
“Guiding to an Adjusted EBITDAC Margin that is down 100 - 150 basis points for 2026.”
“Guiding to an Adjusted EBITDAC Margin of flat to modestly down for full year 2025.”
Breaks if: YoY revenue growth falls below 7.6% next year
Overall, RYAN's fundamentals are strong, but the elevated valuation and sector dependencies introduce risks. Not investment advice.